The Maintenance Phase Nobody Talks About is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
I reached my weight loss target eight weeks ago. The conversations I’ve been having since, with my prescriber and with myself, are different in character from anything I encountered during the loss phase. The literature on maintenance is thinner than the literature on loss. The personal stakes feel higher because the question is no longer “will this work” but “what does this look like for the next decade.”
This is a long post because the topic warrants it.
A friend of mine, Derek in Austin, hit his goal weight of 198 two months before I hit mine. When I called him to compare notes, his first words were, “Man, nobody prepares you for the weird sadness of a flat line on the scale.” He’d lost 47 pounds over seven months on compounded tirzepatide. He was thrilled. And then he stepped down to a maintenance dose, and the momentum just… stopped. “The number stays the same and you wonder what you’re paying for,” he said. I knew exactly what he meant, because I was living it.
The standard framing first: compounded tirzepatide is not FDA-approved. The branded versions are. Compounded preparations are made by licensed 503A/503B compounding pharmacies for individual patients based on prescriber clinical judgment. The maintenance discussion below applies to both regulatory categories but draws on personal experience with the compounded version.
Three Paths, and Only One Has Good Data
When you reach your target weight on a GLP-1 medication, you face three possible paths:
- Stay on the same dose indefinitely.
- Step down to a lower maintenance dose.
- Discontinue the medication entirely.
Each has different evidence behind it, different cost implications, different side effect profiles. Here’s the thing: the honest summary of the literature is that the data on what produces the best long-term weight maintenance is still being collected. And the published outcomes for full discontinuation are not encouraging.
The STEP-1 trial extension and the SURMOUNT-4 trial both examined what happens to patients who stop these medications after substantial weight loss. The pattern in both was significant regain. STEP-1 extension showed roughly two-thirds of the weight loss being regained over the first year off medication. SURMOUNT-4 showed a similar pattern with tirzepatide: continued treatment produced weight maintenance, while discontinuation produced regain.
This is the most frequently cited reason prescribers describe these medications as long-term therapies rather than weight loss tools. The mechanism makes intuitive sense. Appetite regulation is fundamentally biological. The medication produces an exogenous correction to that regulation. Remove the correction, and the original biology reasserts itself. Like letting go of a spring.
What the data does not tell us is whether some subset of patients can successfully discontinue and maintain. Anecdotal reports exist. Published outcome data at scale does not. The prediction of which patients can pull it off is not yet reliable.
My Step-Down, and Why I Chose It
After discussion with my prescriber, my current plan is to step down to 5 mg weekly for maintenance and reassess after 12 months. That’s half my loss-phase dose, a meaningful reduction in medication exposure, while retaining enough appetite regulation to prevent the regain pattern.
Why step down rather than stay put: the loss-phase dose was titrated to produce active weight loss. Maintenance only requires enough appetite regulation to keep weight stable, which is generally a lower threshold. Lowest effective dose makes sense here. Try less, and only increase if the maintenance fails.
Why not discontinue entirely: I have the data in front of me. The regain pattern in the literature is consistent enough that I don’t consider full discontinuation a reasonable plan for the first year. Possibly longer.
The Reality of Week One Through Week Eight
Weight has been stable within a two-pound window since I reduced the dose. Appetite is noticeably stronger than it was on 7.5 mg, but manageable. I’m eating roughly 200 to 300 additional calories per day compared to the loss phase, which is approximately what’s needed to hold steady rather than keep losing.
The mental experience is where this gets interesting. During loss, the medication was doing visible work. The trajectory was downward. The reward loop was strong. During maintenance, the medication is doing maintenance work, which by definition produces no visible day-to-day result. The reward loop is weaker. I underestimated this shift going in.
What helps is reframing the metric. A flat trend line is the win. Not a dip, not a drop. Flat. This requires deliberate effort to recalibrate, because six months of training taught me to look at the scale and see progress. Now progress looks like nothing happening at all. It’s like being a goalkeeper: your best games are the ones where the score stays the same.
Derek told me he started tracking his resting heart rate and sleep quality just to have something that moved. I stole that idea. It works.
The Money Question
The cost of staying on a maintenance dose, in my case, runs about $279 per month. That’s $3,350 annually. In my provider’s pricing structure, the monthly cost is similar regardless of dose, so stepping down didn’t produce savings.
The framing question is whether $3,350 annually is justified. For me, yes. The comorbidity improvements I experienced, and the long-term medical cost avoidance that maintaining a healthier weight implies, tip the balance clearly. The blood pressure improvement alone, if maintained, has significant cardiovascular value over a 20-year horizon.
For other patients with different financial situations or different health profiles, the calculus is different. The maintenance cost is a real expense. It has to fit sustainably in a household budget, month after month, possibly for years. This is part of why some patients attempt the discontinuation path despite the unfavorable outcome data. I understand that decision even if I think the data argues against it.
Obesity as a Chronic Condition (and Why That Reframe Matters)
The closest analogy in everyday medical practice is treatment for hypertension or high cholesterol. These are conditions that respond to medication but rarely “cure” in the sense of allowing the medication to be stopped without consequence. Patients are typically on these medications for decades.
Obesity, as a chronic disease, may be in the same category. The biology of weight regulation does not reset because someone lost weight. The set point the body defends remains higher than the target weight. Exogenous correction is what allows the lower weight to be maintained against that defense.
This is a different framing than the cultural one, which treats weight loss as a project: start, finish, move on. The medical framing increasingly treats obesity as a chronic condition warranting long-term management. Accepting that framing changes everything: the financial commitment, the lifestyle integration, the psychological adjustment to being on a medication with no planned stop date.
What Could Shift the Calculus in Five Years
The literature on these medications is evolving fast. Several open questions could substantially change the maintenance picture:
Whether sub-therapeutic maintenance doses produce stable weight maintenance. If yes, the cost of long-term therapy could drop considerably.
Whether intermittent dosing (monthly, every other week) provides sufficient appetite regulation at maintenance. This is being studied and could transform the practical experience of long-term therapy.
Whether newer agents in development, including multiple new GLP-1 and combination receptor agonists in the pipeline, produce different maintenance profiles.
Whether discontinuation strategies combining dose tapering, lifestyle intervention, and behavioral support can prevent regain.
The honest position right now is that maintenance therapy at the lowest effective dose is the path the evidence supports best. The evidence base is incomplete. The optimal strategy may shift.
Having the Right Conversation With Your Prescriber
The maintenance conversation with a prescriber is qualitatively different from the loss-phase conversation. During loss, the questions are about titration, side effects, and rate of loss. During maintenance, the questions are about long-term strategy, dose minimization, and how to catch early signs of regain.
I’d recommend having an explicit maintenance plan conversation with your prescriber once you’re within ten pounds of your target weight. This conversation should cover: your target weight, the planned post-target dose, how frequently you’ll check in, the criteria for adjusting the dose up or down, and the long-term horizon for the medication.
If your current provider doesn’t engage substantively with these questions, that’s a flag worth attending to. The provider you want for the maintenance phase is one who treats your case as ongoing, not as a transactional series of refills. FormBlends has been substantive about the maintenance discussion in my case, including the explicit acknowledgment that the long-term data is still being collected and that the right strategy involves periodic reassessment rather than a static plan.
The Hardest Part Is the Absence of an Endpoint
The hardest part of maintenance has been the absence of an external finish line. During loss, there was a target weight to reach. During maintenance, there is no comparable milestone. The work is ongoing. The absence of progress markers is mentally taxing in a way I genuinely did not expect.
The interventions that have helped: tracking metrics other than weight (blood pressure, resting heart rate, fasting glucose, sleep quality), maintaining the exercise routine I built during loss, keeping the same eating pattern rather than loosening it now that loss is no longer the goal. And accepting that the work of maintenance is invisible and slow.
The other thing I didn’t anticipate is how the social environment shifts. People who cheered the weight loss now ask when I’ll be “done” with the medication. The honest answer is that I don’t know. Possibly years. Possibly indefinitely. This answer is uncomfortable for people who think of medications as short-term interventions, and it requires a kind of patient education in casual conversation that I wasn’t prepared for. You end up explaining chronic disease management at dinner parties. It’s not the most fun version of yourself.
The Boring Truth
The posture that has helped me is acceptance. This is a chronic condition I’m managing with a chronic medication, alongside lifestyle work that is also chronic. The weight loss was not a project that ended. It transitioned into a maintenance phase I should plan to be in for the foreseeable future.
This reframes the question from “when can I stop” to “what is the most sustainable way to continue.” The answer, for me, is the lowest effective dose with the best-quality provider I can sustain financially, alongside the eating and movement patterns that became normal during the loss phase.
The loss phase was the loud part. The maintenance phase is the long quiet part. Both matter. And the second one is the one that determines whether any of this actually worked.
Frequently Asked Questions
Can I stop tirzepatide after reaching my goal weight? You can, but the discontinuation data is not encouraging. The STEP-1 extension and SURMOUNT-4 trials both showed significant weight regain (roughly two-thirds of lost weight) within the first year off medication. Talk to your prescriber before making this decision.
What is a typical maintenance dose for compounded tirzepatide? It varies by patient. Many prescribers start by reducing to a dose lower than the loss-phase dose, often by half, then adjusting based on weight stability. The goal is the lowest effective dose that prevents regain.
How much does long-term maintenance on compounded tirzepatide cost? Costs vary by provider and pharmacy, but expect ongoing monthly expenses in the range of $200 to $400 depending on dosing and provider pricing structure. Annual costs can be $2,400 to $4,800 or more.
Will I need to be on this medication forever? Current evidence suggests that long-term, possibly indefinite, treatment produces the best weight maintenance outcomes. The medical community increasingly frames obesity as a chronic condition requiring ongoing management, similar to hypertension or high cholesterol.
How often should I see my prescriber during the maintenance phase? Most providers recommend check-ins every four to eight weeks during early maintenance, with the interval potentially extending once weight stability is established. Reassessment of dose and strategy should happen at least annually.
Does appetite come back on a lower maintenance dose? Appetite signaling typically increases somewhat on a reduced dose compared to the loss phase. Most patients describe this as manageable, not a return to pre-medication hunger levels. If appetite increases significantly enough to threaten weight stability, dose adjustment is an option.
Are there new treatments in development that might change the maintenance picture? Yes. Multiple new GLP-1 and combination receptor agonists are in clinical trials, and researchers are studying intermittent dosing schedules and structured discontinuation protocols. The maintenance landscape may look meaningfully different within three to five years.
